Table 1 Clinical trials investigating the efficacy of ICI plus anti-angiogenesis therapy
From: Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Trials Identifier | Disease | Treatment (arm of combination therapy) | Phase | Status |
|---|---|---|---|---|
NCT03024437 | RCC | Atezolizumab + bevacizumab + entinostat | I/II | Recruiting |
NCT03363867 | OC | Atezolizumab + bevacizumab + cobimetinib | II | Recruiting |
NCT03472560 | NSCLC/UC | Avelumab + axitinib | II | Recruiting |
NCT03395899 | BC | Atezolizumab + bevacizumab + cobimetinib | II | Recruiting |
NCT02724878 | NCCKC | Atezolizumab + bevacizumab | II | Recruiting |
NCT03386929 | NSCLC | Avelumab + axitinib + palbociclib | I/II | Recruiting |
NCT03574779 | OC | TSR-042+ bevacizumab + Niraparib | II | Recruiting |
NCT02921269 | CC | Atezolizumab + bevacizumab | II | Active, not recruiting |
NCT03647956 | NSCLC | Atezolizumab + bevacizumab + carboplatin + pemetrexed | II | Recruiting |
NCT02734004 | OC/BC/SCLC/GC | MEDI4736 + bevacizumab + olaparib | I/II | Recruiting |
NCT03517449 | EC | Pembrolizumab + lenvatinib | III | Recruiting |
NCT02572687 | GC/GEJ/NSCLC/HCC | MEDI4736 + ramucirumab | I | Active, not recruiting |
NCT02839707 | OC/FTC/PC | Atezolizumab + bevacizumab + PLD | II/III | Recruiting |
NCT03289533 | HCC | Avelumab + axitinib | I | Recruiting |
NCT02210117 | RCC | Ipilimumab + bevacizumab | I | Active, not recruiting |
NCT01950390 | Melanoma | Ipilimumab + bevacizumab | II | Active, not recruiting |
NCT03394287 | BC | SHR-1210 + apatinib | II | Recruiting |
NCT03417895 | SCLC | SHR-1210 + apatinib | II | Not yet recruiting |
NCT03491631 | Multiple solid tumors | SHR-1210 + apatinib + SHR9146 | I | Not yet recruiting |
NCT02942329 | HCC/GC | SHR-1210 + apatinib | I/II | Recruiting |
NCT03671265 | ESCC | SHR-1210 + apatinib + radiation | NA | Not yet recruiting |
NCT03359018 | Osteosarcoma | SHR-1210 + apatinib | II | Active, not recruiting |
NCT03722875 | HCC | SHR-1210 + apatinib | NA | Not yet recruiting |
NCT03502746 | Mesothelioma | Nivolumab + ramucirumab | II | Recruiting |
NCT03606174 | UC | Nivolumab + sitravatinib | II | Recruiting |
NCT02853331 | RCC | Pembrolizumab + axitinib | III | Active, not recruiting |
NCT03680521 | RCC | Nivolumab + sitravatinib | II | Recruiting |
NCT02493751 | RCC | Avelumab + axitinib | I | Active, not recruiting |
NCT02684006 | RCC | Avelumab + axitinib | III | Active, not recruiting |
NCT02366143 | NSCLC | Atezolizumab + bevacizumab + paclitaxel + carboplatin | III | Active, not recruiting |
NCT00790010 | Melanoma | Ipilimumab + bevacizumab | I | Active, not recruiting |
NCT 01633970 | Multiple solid tumors | Atezolizumab + bevacizumab | I | Active, not recruiting |